{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SC&page=62",
    "query": {
      "intervention": "SC",
      "page": 62
    },
    "page_size": 10
  },
  "pagination": {
    "page": 62,
    "page_size": 10,
    "total_count": 3865,
    "total_pages": 387,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SC&page=63&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SC&page=61&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-03T21:50:37.773Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05789537",
      "title": "A Study of SerpinPC in Participants with Hemophilia B (HemB) with Inhibitors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hemophilia B with Inhibitor",
        "Hemophilia B"
      ],
      "interventions": [
        {
          "name": "SerpinPC",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ApcinteX Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "65 Years",
        "sex": "MALE",
        "summary": "12 Years to 65 Years · Male only"
      },
      "enrollment_count": 3,
      "start_date": "2023-07-28",
      "completion_date": "2025-02-24",
      "has_results": false,
      "last_update_posted_date": "2025-03-11",
      "last_synced_at": "2026-11-03T21:50:37.773Z",
      "location_count": 3,
      "location_summary": "Aurora, Colorado • Tampa, Florida • Greenville, North Carolina",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Greenville",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05789537"
    },
    {
      "nct_id": "NCT06111586",
      "title": "Frexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults and Adolescents on Top of Insulin Therapy (FABULINUS)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Type 1 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Frexalimab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Insulin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "35 Years",
        "sex": "ALL",
        "summary": "12 Years to 35 Years"
      },
      "enrollment_count": 197,
      "start_date": "2023-12-11",
      "completion_date": "2030-10-29",
      "has_results": false,
      "last_update_posted_date": "2026-11-02",
      "last_synced_at": "2026-11-03T21:50:37.773Z",
      "location_count": 14,
      "location_summary": "San Francisco, California • Aurora, Colorado • Gainesville, Florida + 11 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06111586"
    },
    {
      "nct_id": "NCT06127095",
      "title": "A Study to Assess New Participant's Perspectives Beyond Clinical Efficacy of Monoclonal Antibody-Based Relapsing Remitting Multiple Sclerosis (RRMS) Treatments",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Multiple Sclerosis, Relapsing-Remitting"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 474,
      "start_date": "2023-11-24",
      "completion_date": "2024-11-28",
      "has_results": false,
      "last_update_posted_date": "2024-12-18",
      "last_synced_at": "2026-11-03T21:50:37.773Z",
      "location_count": 1,
      "location_summary": "Cambridge, Massachusetts",
      "locations": [
        {
          "city": "Cambridge",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06127095"
    },
    {
      "nct_id": "NCT03908112",
      "title": "Interventions for Convergence Insufficiency in Concussed Children",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Concussion",
        "Convergence Insufficiency"
      ],
      "interventions": [
        {
          "name": "Standard Community Concussion Care (SC)",
          "type": "BEHAVIORAL"
        },
        {
          "name": "SC plus Simple Convergence Exercises (SC+)",
          "type": "BEHAVIORAL"
        },
        {
          "name": "SC plus Office-based Vergence/Accommodative Therapy (SC+OBVAT)",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Mitchell Scheiman",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "11 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "11 Years to 17 Years"
      },
      "enrollment_count": 264,
      "start_date": "2021-04-01",
      "completion_date": "2025-03-31",
      "has_results": false,
      "last_update_posted_date": "2020-10-23",
      "last_synced_at": "2026-11-03T21:50:37.773Z",
      "location_count": 8,
      "location_summary": "Birmingham, Alabama • Fullerton, California • Palo Alto, California + 5 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Newark",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03908112"
    },
    {
      "nct_id": "NCT00217542",
      "title": "Azacitidine and Recombinant Interferon Alfa-2b in Treating Patients With Stage III or Stage IV Melanoma or Stage IV Kidney Cancer That Cannot Be Removed By Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Recurrent Melanoma",
        "Recurrent Renal Cell Cancer",
        "Stage III Melanoma",
        "Stage IV Melanoma",
        "Stage IV Renal Cell Cancer"
      ],
      "interventions": [
        {
          "name": "recombinant interferon alfa-2b",
          "type": "BIOLOGICAL"
        },
        {
          "name": "amifostine/azacitidine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 42,
      "start_date": "2005-07",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-05-03",
      "last_synced_at": "2026-11-03T21:50:37.773Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00217542"
    },
    {
      "nct_id": "NCT06692153",
      "title": "Embecta AID System in Adults With Type 2 Diabetes",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Type 2 Diabetes",
        "Type 2 Diabetes Mellitus (T2DM)",
        "Type 2 DM",
        "T2DM With Inadequate Glycemic Control",
        "T2DM (Type 2 Diabetes Mellitus)",
        "T2D",
        "T2DM"
      ],
      "interventions": [
        {
          "name": "An AID System.",
          "type": "DEVICE"
        },
        {
          "name": "Standard of Care (SC)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "OTHER"
      ],
      "sponsor": "Embecta Corp.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2025-01",
      "completion_date": "2026-05",
      "has_results": false,
      "last_update_posted_date": "2024-12-16",
      "last_synced_at": "2026-11-03T21:50:37.773Z",
      "location_count": 9,
      "location_summary": "Palo Alto, California • Walnut Creek, California • Indianapolis, Indiana + 6 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Long Island City",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06692153"
    },
    {
      "nct_id": "NCT00167557",
      "title": "Orthotopic Liver Transplant (OLT) Recipients With Hepatitis C Virus (HCV) Under Preemptive Treatment",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hepatitis C"
      ],
      "interventions": [
        {
          "name": "Pegylated Interferon",
          "type": "DRUG"
        },
        {
          "name": "Ribavirin",
          "type": "DRUG"
        },
        {
          "name": "Liver Biopsy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "The University of Texas Health Science Center, Houston",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 0,
      "start_date": "2005-01",
      "completion_date": "2008-03",
      "has_results": false,
      "last_update_posted_date": "2013-11-19",
      "last_synced_at": "2026-11-03T21:50:37.773Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00167557"
    },
    {
      "nct_id": "NCT00594555",
      "title": "A Study Evaluating the Effects of CLAG With Gleevec in Refractory or Relapsed Acute Myeloid Leukemia",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Myeloid Leukemia, Blast Crisis",
        "Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "Imatinib Mesylate",
          "type": "DRUG"
        },
        {
          "name": "CLAG",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Cincinnati",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2007-11",
      "completion_date": "2008-11",
      "has_results": false,
      "last_update_posted_date": "2008-10-31",
      "last_synced_at": "2026-11-03T21:50:37.773Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00594555"
    },
    {
      "nct_id": "NCT02891226",
      "title": "A Study of Mirikizumab (LY3074828) in Participants With Active Crohn's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Crohn's Disease"
      ],
      "interventions": [
        {
          "name": "Mirikizumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 191,
      "start_date": "2016-12-14",
      "completion_date": "2021-02-05",
      "has_results": true,
      "last_update_posted_date": "2022-08-30",
      "last_synced_at": "2026-11-03T21:50:37.773Z",
      "location_count": 44,
      "location_summary": "Huntsville, Alabama • Tucson, Arizona • Garden Grove, California + 38 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "Ventura",
          "state": "California"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02891226"
    },
    {
      "nct_id": "NCT02500576",
      "title": "Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Treating Patients With Metastatic Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Melanoma",
        "Stage IIIB Cutaneous Melanoma AJCC v7",
        "Stage IIIC Cutaneous Melanoma AJCC v7",
        "Stage IV Cutaneous Melanoma AJCC v6 and v7"
      ],
      "interventions": [
        {
          "name": "Aldesleukin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine Phosphate",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Therapeutic Tumor Infiltrating Lymphocytes",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2015-08-07",
      "completion_date": "2022-10-12",
      "has_results": true,
      "last_update_posted_date": "2025-01-15",
      "last_synced_at": "2026-11-03T21:50:37.773Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02500576"
    }
  ]
}